A retrospective analysis on anti-CD20 antibody–treated Epstein–Barr virus–related posttransplantation lymphoproliferative disorder following ATG-based haploidentical T-replete hematopoietic stem cell transplantation
Abstract Posttransplantation lymphoproliferation disorder (PTLD) is a life-threatening complication after hematopoietic stem cell transplantation (HSCT). Anti-CD20 antibody is the most widely used antibody to eliminate infected B cells. Few studies have focused on prognostic factors predicting the outcome of EBV (Epstein–Barr virus)-PTLD. We conducted a retrospective analysis of 2571 haplo-HSCTs performed between 2010 and 2017 at the Peking University Institute of Hematology; seventy patients who had been treated with rituximab for PTLD were enrolled. The overall EBV-related PTLD frequency was 3.1%. With a median follow-up time of 365 days (range, 54–2659), the overall survival rate was 51.43% (36/70). The cumulative incidence of EBV-PTLD complete remission with anti-CD20 antibody monotherapy was 68.57% (48/70). EBV-PTLD-related mortality was 11.43% (8/70), while the transplantation-related mortality was 38.57% (27/70). Multivariate analysis showed that a decrease in EBV viral load 1 week after therapy was associated with high response rate of EBV-PTLD (p = 0.007, 0.106 (0.021–0.549)), low PTLD-related mortality (p = 0.010, HR 0.058 (0.007–0.503)), and transplantation-related mortality (p = 0.051, HR 0.441 (0.194–1.003)). For EBV-PTLD patients after haplo-HSCT who received rituximab as first-line therapy, non-decreased EBV viral load 1 week after anti-CD20 therapy could be high risk factor for poor outcomes..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:99 |
|---|---|
| Enthalten in: |
Annals of hematology - 99(2020), 11 vom: 24. März, Seite 2649-2657 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Luo, Xue-Yi [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Epstein-Barr virus |
|---|
| Anmerkungen: |
© Springer-Verlag GmbH Germany, part of Springer Nature 2020 |
|---|
| doi: |
10.1007/s00277-020-04003-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2119803439 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2119803439 | ||
| 003 | DE-627 | ||
| 005 | 20230504172110.0 | ||
| 007 | tu | ||
| 008 | 230504s2020 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00277-020-04003-8 |2 doi | |
| 035 | |a (DE-627)OLC2119803439 | ||
| 035 | |a (DE-He213)s00277-020-04003-8-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Luo, Xue-Yi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a A retrospective analysis on anti-CD20 antibody–treated Epstein–Barr virus–related posttransplantation lymphoproliferative disorder following ATG-based haploidentical T-replete hematopoietic stem cell transplantation |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © Springer-Verlag GmbH Germany, part of Springer Nature 2020 | ||
| 520 | |a Abstract Posttransplantation lymphoproliferation disorder (PTLD) is a life-threatening complication after hematopoietic stem cell transplantation (HSCT). Anti-CD20 antibody is the most widely used antibody to eliminate infected B cells. Few studies have focused on prognostic factors predicting the outcome of EBV (Epstein–Barr virus)-PTLD. We conducted a retrospective analysis of 2571 haplo-HSCTs performed between 2010 and 2017 at the Peking University Institute of Hematology; seventy patients who had been treated with rituximab for PTLD were enrolled. The overall EBV-related PTLD frequency was 3.1%. With a median follow-up time of 365 days (range, 54–2659), the overall survival rate was 51.43% (36/70). The cumulative incidence of EBV-PTLD complete remission with anti-CD20 antibody monotherapy was 68.57% (48/70). EBV-PTLD-related mortality was 11.43% (8/70), while the transplantation-related mortality was 38.57% (27/70). Multivariate analysis showed that a decrease in EBV viral load 1 week after therapy was associated with high response rate of EBV-PTLD (p = 0.007, 0.106 (0.021–0.549)), low PTLD-related mortality (p = 0.010, HR 0.058 (0.007–0.503)), and transplantation-related mortality (p = 0.051, HR 0.441 (0.194–1.003)). For EBV-PTLD patients after haplo-HSCT who received rituximab as first-line therapy, non-decreased EBV viral load 1 week after anti-CD20 therapy could be high risk factor for poor outcomes. | ||
| 650 | 4 | |a Posttransplantation lymphoproliferation disorder | |
| 650 | 4 | |a Epstein-Barr virus | |
| 650 | 4 | |a Haplo identical hematopoietic stem cell transplantation | |
| 650 | 4 | |a Rituximab | |
| 650 | 4 | |a Risk factor analysis | |
| 700 | 1 | |a Mo, Xiao-Dong |4 aut | |
| 700 | 1 | |a Xu, Lan-Ping |4 aut | |
| 700 | 1 | |a Zhang, Xiao-Hui |4 aut | |
| 700 | 1 | |a Wang, Yu |4 aut | |
| 700 | 1 | |a Liu, Kai-Yan |4 aut | |
| 700 | 1 | |a Chang, Ying-Jun |4 aut | |
| 700 | 1 | |a Zhao, Xiang-Yu |4 aut | |
| 700 | 1 | |a Huang, Xiao-Jun |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of hematology |d Springer Berlin Heidelberg, 1991 |g 99(2020), 11 vom: 24. März, Seite 2649-2657 |w (DE-627)130956759 |w (DE-600)1064950-5 |w (DE-576)025101188 |x 0939-5555 |7 nnns |
| 773 | 1 | 8 | |g volume:99 |g year:2020 |g number:11 |g day:24 |g month:03 |g pages:2649-2657 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s00277-020-04003-8 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a GBV_ILN_2018 | ||
| 912 | |a GBV_ILN_4277 | ||
| 951 | |a AR | ||
| 952 | |d 99 |j 2020 |e 11 |b 24 |c 03 |h 2649-2657 | ||